Application of CDK4/6 Inhibitors in Premenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: a Real-World Experience

被引：0

作者：

Kurbacher, Christian M. ^{[1
]}

Fischer, Lotta Ada ^{[2
]}

Heinrich, Georg ^{[3
]}

Herz, Susanne ^{[1
]}

Schott, Alexander ^{[1
]}

Kurbacher, A. Tabea ^{[1
]}

Kurbacher, Jutta Anna ^{[4
]}

Rudlowski, Christian ^{[5
]}

Warm, Mathias R. ^{[2
]}

机构：

[1] Gynakol Zentrum Bonn Friedenspl, Gynakol Schwerpunkt Gynakol Onkol 1, Bonn, Germany

[2] Stadt Klinikum Holweide, Brustzentrum, Cologne, Germany

[3] Praxis Gynakol Onkol, Furstenwalde, Germany

[4] Gynakol Zentrum Bonn Friedenspl, Gynakol Allgemeine Gynakol & Geburtshilfe 2, Bonn, Germany

[5] Evangel Krankenhaus Bergisch Gladbach, Frauenklin, Bergisch Gladbach, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

552

引用

页码：19 / 19

页数：1

共 50 条

[11] Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer
Sahin, Taha Koray
Rizzo, Alessandro
Guven, Deniz Can
Aksoy, Sercan
CANCER TREATMENT REVIEWS, 2025, 135
[12] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
Grinshpun, Albert
Tolaney, Sara M. M.
Burstein, Harold J. J.
Jeselsohn, Rinath
Mayer, Erica L. L.
NPJ BREAST CANCER, 2023, 9 (01)
[13] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
Albert Grinshpun
Sara M. Tolaney
Harold J. Burstein
Rinath Jeselsohn
Erica L. Mayer
npj Breast Cancer, 9
[14] CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects
Wekking, Demi
Leoni, Vera Piera
Lambertini, Matteo
Dessi, Mariele
Pretta, Andrea
Cadoni, Andrea
Atzori, Luigi
Scartozzi, Mario
Solinas, Cinzia
CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 75 : 57 - 64
[15] Real World Statistics on CDK4/6 Inhibitor Use in Metastatic Hormone Receptor Positive and HER2-Negative Breast Cancer with a Focus on Age
Monahan, Kathleen
Kamaraju, Sailaja
Cheng, Yee Chung
Retseck, Janet
Sriram, Deepika
Burfeind, John
Chitambar, Christopher
Chaudhary, Lubna N.
CANCER RESEARCH, 2023, 83 (05)
[16] Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer.
Ferraro, Emanuela
Moiso, Enrico
Safonov, Anton
Cabel, Luc
Loudon, Laura
Dang, Chau T.
Shen, Sherry
Jhaveri, Komal L.
Robson, Mark E.
Chandarlapaty, Sarat
Razavi, Pedram
Modi, Shanu
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[17] The association of hormone receptor expression level and clinical efficacy of CDK4/6 inhibitor in hormone receptor-positive, HER2-negative metastatic breast cancer
Bao, Kelvin K. H.
Wong, Carol H. Y.
Yung, Jackie
Tam, Venus
Cheung, Ka Man
Chan, Jeffrey C. H.
Yiu, Harry H. Y.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[18] Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Ma, Jun
Chan, Jack Junjie
Toh, Ching Han
Yap, Yoon-Sim
NPJ BREAST CANCER, 2023, 9 (01)
[19] Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Jun Ma
Jack Junjie Chan
Ching Han Toh
Yoon-Sim Yap
npj Breast Cancer, 9
[20] Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors
Werutsky, Gustavo
Reinert, Tomas
Rosa, Mahira Lopes
Barrios, Carlos Henrique
CLINICAL BREAST CANCER, 2021, 21 (06) : E688 - E692

← 1 2 3 4 5 →